The RELIVE consortium for relapsed or refractory pediatric hepatoblastoma and hepatocellular carcinoma: a scoping review of the problem and a proposed solution

Liver tumors account for approximately 2% of all pediatric malignancies. Children with advanced stages of hepatoblastoma (HB) are cured only 50–70% of the time while children with advanced hepatocellular carcinoma (HCC) have a

Saved in:
Bibliographic Details
Published in:EClinicalMedicine 2024-03, Vol.69, p.102446-102446, Article 102446
Main Authors: O’Neill, Allison F., Trobaugh-Lotrario, Angela, Geller, James I., Hiyama, Eiso, Watanabe, Kenichiro, Aerts, Isabelle, Fresneau, Brice, Toutain, Fabienne, Sullivan, Michael J., Katzenstein, Howard M., Morland, Bruce, Branchereau, Sophie, Zsiros, József, Maibach, Rudolf, Ansari, Marc
Format: Article
Language:English
Subjects:
Carcinoma
Hepatoblastoma
Pediatric
Registry
Relapse
Review
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Liver tumors account for approximately 2% of all pediatric malignancies. Children with advanced stages of hepatoblastoma (HB) are cured only 50–70% of the time while children with advanced hepatocellular carcinoma (HCC) have a
ISSN:2589-5370
2589-5370
DOI:10.1016/j.eclinm.2024.102446